Anthropic's New Life Sciences Lab: Claude Agents Discover a Novel Enzyme System

Anthropic disclosed an early result from a new life sciences research lab it established in spring 2026: Claude agents identified a previously unrecognized enzyme system by searching a massive DNA sequence database.

Details

• The lab: based in the Bay Area, staffed by computational biologists who previously worked on CRISPR research and gene therapy, operating at biosafety levels 1-2 with all experimental work done by human scientists
• The discovery: array-associated reverse transcriptases (ART), found primarily in bacteriophages, consisting of a reverse transcriptase enzyme, an accessory protein of unknown function, and an array of non-coding DNA repeats
• What’s novel: the reverse transcriptase itself was known, but Claude was apparently first to notice the structured array of repeating DNA sequences flanking it — a configuration resembling CRISPR arrays that may similarly produce short RNAs, suggesting programmable function; this specific combination had previously been seen in only a handful of other DNA-manipulating biological systems
• How it was found: Claude agents searched the database for 21 hours across roughly 950 agent sessions consuming 210 million tokens, reviewing over 200,000 reverse transcriptases, narrowing to 3,500 candidate systems, and ultimately 20 compelling candidates — one agent spotted the unusual repeat pattern, ran comparative analysis, and produced a report for human lab verification
• Outside reaction: CRISPR pioneer Feng Zhang (MIT/Broad Institute) called it “an exciting example of how AI agents can contribute” to biological discovery
• Caveats: the ART system’s actual function remains unknown, and Anthropic released the finding as a preprint — an early-stage result meant to demonstrate Claude’s capability in this kind of search rather than a conclusive scientific breakthrough, with human scientists involved throughout

What happened next

The disclosure gives Anthropic a concrete example to point to for AI-assisted biological discovery, arriving alongside its recently launched Life Sciences Verification Program — together signaling the company is building out both the research capability and the access infrastructure to position Claude as a tool for frontier biology work, not just as a general-purpose assistant.